|
FDA Highlights Cardio Risks With Novo Insulin Drugs, Analysts Eye Challenging Approval
Novo Nordisk’s ultra-long acting insulin candidates Tresiba and Ryzodeg appear to be associated with an increase in cardiovascular risk, FDA reviewers said in briefing documents leading up to a Thursday advisory panel meeting.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives